This is a working overview of Epithalamin, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-12-06. Anything still debated is marked as such rather than presented as settled.
Epitalon is a synthetic tetrapeptide with the sequence alanine-glutamate-aspartate-glycine, commonly abbreviated AEDG. It was designed at the St. Petersburg Institute of Bioregulation and Gerontology as a short, chemically defined analogue of epithalamin, a fraction obtained from bovine pineal tissue. Small peptide bioregulators of this type formed a long-running line of work there from the 1980s onward. Because the molecule is produced by solid-phase synthesis rather than extraction, its composition is exact and its purity can be measured directly.
The most frequently cited proposed action is induction of telomerase, the enzyme that adds repeat sequences to chromosome ends. Cell-culture work from the originating group reported higher telomerase reverse transcriptase expression and measurable telomere elongation in human somatic cells after exposure. How a four-residue peptide would reach nuclear gene regulation is not established, and no cell-surface receptor or uptake route has been identified. Additional reports describe changes in melatonin secretion, antioxidant enzyme activity and lipid peroxidation in aged animals, but these findings remain mechanistically unconnected to the telomerase observation.
The compound is described in the literature as a derivative of epithalamin, a preparation obtained from bovine pineal tissue. Work on this peptide family was carried out mainly by a research group in Saint Petersburg beginning in the 1980s, and the substance was later registered for clinical use in Russia under the name Epitalon. Outside that region it is generally treated as a research chemical rather than an approved medicine. Statements about its biological activity rest on a relatively small number of studies, and independent replication remains limited.
In its supplied form epitalon is a white to off-white powder, usually lyophilized and often hygroscopic. It dissolves readily in water and in aqueous buffers, and it is commonly handled as the acetate or trifluoroacetate salt to improve stability during purification and drying. The amide backbone is labile in aqueous media, so solutions are less durable than the dry solid. Handling notes in the chemical literature therefore emphasize keeping the powder dry, cool and shielded from light until it is dissolved.
Epitalon is a synthetic tetrapeptide whose sequence is alanine-glutamate-aspartate-glycine, written in single-letter code as AEDG. The four residues are joined by three peptide bonds, giving a linear backbone with no branching and no disulfide bridges. Its calculated molecular mass for the free form is approximately 390.3 daltons, a figure that rises when the compound is supplied as an acetate or trifluoroacetate salt. Because the chain is short, the molecule is defined entirely by its residue order rather than by any folded three-dimensional structure.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C14H22N4O9 | Calculated from the four residues with three water losses |
| Molecular mass | About 390.35 g/mol | Monoisotopic mass near 390.14, used for mass-spectrometric identification |
| Peptide sequence | Ala-Glu-Asp-Gly | Single-letter form AEDG; no disulfide bonds or modified residues |
| Appearance | White to off-white solid | Supplied as a dried powder |
| Isoelectric point | Around 4 | Estimated from aspartate and glutamate side-chain pKa values |
（TG:@pojiaai）Epitalon is a synthetic linear tetrapeptide with the sequence alanine-glutamate-aspartate-glycine, abbreviated AEDG. It emerged from work on epithalamin, a peptide fraction prepared from bovine pineal tissue, and was designed as a short, chemically defined analogue of that extract. Early publications came mainly from Russian laboratories studying pineal peptides and aging-related endpoints. The compound appears in the literature under several spellings, including epithalon and epithalone, which complicates systematic searching. Its small size makes solid-phase assembly and routine analytical characterization straightforward.
Chemically, the molecule consists of four amino acid residues joined by three peptide bonds, with a free N-terminal amino group and a free C-terminal carboxyl group. Its molecular formula is C14H22N4O9, and its monoisotopic mass is approximately 390 daltons. The acidic glutamate and aspartate side chains give the peptide a net negative charge near neutral pH, a property that shapes its chromatographic behaviour and solubility profile. No disulfide bridges or other post-translational modifications are present, so the primary sequence alone defines the structure.
Most experimental work has been carried out in cell culture and animal models. Several reports describe changes in telomerase activity and proliferation in cultured cells, while rodent studies have examined lifespan, melatonin rhythm and reproductive endpoints. Human data remain limited, and much of the published clinical material consists of small trials with incomplete reporting of methods and controls. Whether the cell and animal findings translate into measurable effects in people is an open question, and the mechanistic basis of the reported telomerase changes is not fully established.
is a matrix, whose elements are so called influence coefficients relating the contact pressure and the deformation. The strict LCP formulation of the CM problem presented above, allows for direct application of well-established numerical solution techniques such as Lemke's pivoting algorithm. The Lemke algorithm has the advantage that it finds the numerically exact solution within a finite number of iterations. The MATLAB implementation presented by Almqvist et al. is one example that can be employed to solve the problem numerically. In addition, an example code for an LCP solution of a 2D linear elastic contact mechanics problem has also been made public at MATLAB file exchange by Almqvist et al.
Entry for Albany in the Oregon Blue Book Official Website Albany Chamber of Commerce Albany Visitors Association Linn County Roots entry for Albany Archived July 13, 2011, at the Wayback Machine Albany Carousel Documentary produced by Oregon Public Broadcasting Spence, Mark. "Albany". The Oregon Encyclopedia. "Albany (Oregon)" . New International Encyclopedia. 1905. "Albany (Oregon)" . Encyclopedia Americana. 1920. Albany Covered Bridge Route
Tegafur is a chemotherapeutic prodrug of 5-fluorouracil (5-FU) used in the treatment of cancers. It is a component of the combination drug tegafur/uracil. When metabolised, it becomes 5-FU. It was patented in 1967 and approved for medical use in 1972.
In 1999, Busslinger and his lab described the first molecular definition of a lineage commitment process by identifying Pax5 as the B cell lineage commitment factor that restricts the developmental options of early lymphoid progenitors to the B cell pathway by repressing lineage-inappropriate genes and that simultaneously promotes B cell development by activating B-cell-specific genes. To date, Pax5 is known to function as a guardian of B cell identity for early to late B cell development and to function as an important tumor suppressor or oncoprotein in B cell leukemia. In addition to Pax5, the Busslinger group investigated the role of other important transcription factors, such as E2A, EBF1, Ikaros, and Blimp1, in regulating distinct aspects of B cell development and immunity. Busslinger also contributed to the current knowledge of how the large locus encoding the immunoglobulin heavy chain (IgH) protein undergoes spatial contraction by looping in early B cell development. This long-range looping induces the juxtaposition of Variable (V) gene segments next to Diversity (D) gene segments, which facilitates V-to-DJ recombination to generate a functional IgH gene. Busslinger identified Pax5 as a critical regulator of IgH locus contraction that facilitates chromatin loop extrusion across the entire locus. He is a member of the editorial board for Immunity.
Sources: en.wikipedia.org
Lately Intelligence Officer, Home Office. For services to Border Security. The Reverend Christopher Richard Colledge. For services to the community in Bournemouth, Dorset. Alan Collier. Director, Procurement and Sustainability, Norfolk County Council. For services to Local Government. Dr. Michael Patrick Collins. Lately Science Lead on EU and International Science Partnerships, Department for Environment, Food and Rural Affairs. For services to International Science Policy. Denise Cooke. Administrative Officer, Maritime and Coastguard Agency. For Public Service. Laura Coryton. Tampon Tax Campaigner, Author and Co-Founder, Sex Ed Matters. For services to Charitable Campaigning. Margaret Irene Cosin. Lately Member, Dover District Council. For Political and Public Service. Stuart Samuel Cossar. Investigation Manager, Police Service of Scotland. For services to the Investigation and to the Bereaved Families of the Lockerbie Air Disaster. Anne Marie Coulter. Volunteer, Summerhill Community Centre. For services to the community in Dumfries. Samuel Robert John Cousley. Head of Seafarers, Department for Transport. For services to Seafarers. Professor Rachel Elizabeth Cowgill. Professor of Music, University of York. For services to Culture, to Education and to the Arts. John Hubert Cox. Chair, Joseph Cox Charity. For services to Homeless People in Manchester. Maureen Joan Cox. For charitable services in the London Borough of Hackney. Vanessa Sara Crocker. Co-Founder, Spread a Smile. For services to Seriously and Terminally Ill Children and their Families. Daniel Steven Paul Croft.
Petersburg, Florida, was subject to an FCA claim that resulted in a total judgment of US$1.179 million on 214 fraudulent claims to Medicare that totaled US$755.54 stemming from the lack of a CLIA certificate. The oncology practice had its own CLIA certificate and acquired another oncology clinic with an in-house lab, but did not obtain the clinic's CLIA license, so the existing CLIA certificate did not cover the new practice. Because the lab at the newly acquired oncology practice lacked a proper CLIA certificate, reimbursement was denied. The practice opted to resubmit the bills to fraudulently claim the tests were performed at an office with a valid CLIA certificate. In doing so 214 times, the federal government suffered $755.54 in damages. The court trebled the damages to $2,266.62 and imposed the minimum statutory penalty of $5,500 per violation for each of the 214 violations. The Eleventh circuit noted that "[s]eeing a judgment of $1.179 million based on $755.54 in actual damages may raise an eyebrow," noting that "[f]raud harms the United States in ways untethered to the value of any ultimate payment" and that "[i]n the context of the FCA, we also consider the deterrent effect of a monetary award."
Pindolol is a first generation, non-selective beta blocker in the class of β-adrenergic receptor antagonists. On the receptor level it is a competitive partial agonist. It possesses intrinsic sympathomimetic activity, meaning it has some degree of agonist effects in the absence of competing ligands. Pindolol shows membrane-stabilizing effects like quinidine, possibly accounting for its antiarrhythmic effects. It also acts as a serotonin 5-HT1A receptor partial agonist (intrinsic activity = 20–25%) or functional antagonist. The drug additionally shows affinity for the serotonin 5-HT1B receptor.
=== Venetoclax === BCL-2 is a cellular protein that can act to inhibit cell death due to apoptosis. The BCL-2 gene appears to be one of the most up-regulated (i.e. overactive) genes in BPDCN. Venetoclax inhibits the apoptosis-inhibiting action of BCL-2 and proved active in treating two patients with relapsed or refractory BPDCN. A phase I clinical trial testing the safety and efficacy of the drug in BPDCN is planned but not yet in its recruiting phase.
=== Eligibility of minors === While the WPATH standards of care generally require the patient to have reached the age of medical majority, they include a separate section devoted to children and adolescents. Prepubescent children do not have access to medical intervention for gender-affirming therapy. After puberty, some medical intervention is available for adolescents depending on specific criteria for gender incongruence diagnosis, capacity for informed consent, and mental and physical health. According to a study by JAMA Pediatrics published in January 2025, less than 0.1% of adolescents covered by private medical insurance in the US take gender-affirming medication to treat gender dysphoria.
Sources: en.wikipedia.org
No. Epithalamin is a peptide-containing extract of bovine pineal glands, while epitalon is a single synthetic tetrapeptide. The extract contains many peptides and other tissue components, so its composition varies between batches in ways that a synthesised sequence does not.
It is not recognised as an endogenous peptide hormone. The four-residue sequence can appear inside larger proteins and in digestive fragments of dietary protein, but no dedicated pathway producing it as a signalling molecule has been identified.
Several cell-culture reports describe increased telomerase activity after treatment, measured by enzyme assays or by transcript levels. Results differ between cell types and laboratories, and measured telomere lengthening has been reported in some studies but not in others, which leaves the physiological relevance open.
The peptide contains four residues in the order alanine, glutamate, aspartate and glycine, abbreviated AEDG. The chain is linear and held together by three peptide bonds. Its calculated mass for the uncharged free form is about 390.3 daltons.